




Temsavir blocks HIV-1 soluble gp120-induced immunomodulatory activities






Veillette et al., JVi 2014, 2015















Veillette et al., JVi 2014, 2015










Richard et al., EBioMedicine 2016






TMR protects bystander cells from ADCC











Co-culture with Mock-infected cells














Blocking recombinant gp120
















Blocking shed gp120















Blocking shed gp120











Blocking shed gp120



















Temsavir « detoxifies » shed gp120














Temsavir affects the antigenicity of shed gp120

ELISA with CD4-Ig



Coating of primary CD4+ T cells










TMR

???








Temsavir vs gp120-mediated cytokine burst






Temsavir blocks gp120-mediated cytokine burst







Temsavir blocks gp120-mediated cytokine burst








- Donor 3

→ Donor 2


Temsavir blocks gp120-mediated induction of IL-10 by monocytes








CONCLUSIONS









Acknowledgments

Finzi Lab

Catherine Bourassa
Gabrielle Gendron-Lepage
Guillaume Goyette
Halima Medjahed
Jérémie Prévost
Jonathan Richard

Yale University
Walther Mothes

<u>CRCHUM</u> **Daniel Kaufmann** Nathalie Brassard

Mathieu Dubé Fleur Gaudette

University of Pennsylvania

Amos B. Smith, III

Hung-Ching Chen

<u>USUHS</u> **Marzena Pazgier** William D Tolbert

FRSQ SIDA-MI network
Mario Legault

ViiV Healthcare
Andrew Clark













Chaires de recherche du Canada











Temsavir affects the antigenicity of shed gp120
















Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies

Marianne Boutin, ^{a,b} Dani Vézina, ^a Shilei Ding, ^a Jérémie Prévost, ^{a,b} Annemarie Laumaea, ^{a,b} Lorie Marchitto, ^{a,b} Sai Priya Anand, ^c Halima Medjahed, ^a Gabrielle Gendron-Lepage, ^a Catherine Bourassa, ^a Guillaume Goyette, ^a Andrew Clark, ^d Jonathan Richard, ^{a,b}
Dandrés Finzi
Andrew Clark, ^d Jonathan Richard, ^{a,b}













Impact of temsavir treatment on Env conformation at the cell surface








Impact of temsavir treatment on Env conformation at the cell surface









Impact of temsavir treatment on Env conformation at the surface of viral particles







Temsavir modulates Env conformation at the surface of infected primary CD4+ T cells







bNAbs-mediated ADCC is significantly decreased by temsavir

